Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., headquartered in Tokyo, has established a wholly-owned subsidiary Eisai Ltd. in Mississauga, Ontario.

“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region,” said Hajime Shimizu, chairman and chief executive officer, Eisai, Inc. “Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”

Eisai Ltd. is working with Health Canada on the approval of select products from Eisai Inc.’s portfolio for the Canadian market with plans for additional currently marketed products to be introduced to the Canadian market as well. The company’s areas of focus will include neurology, gastrointestinal disorders and oncology/critical care.